Amendment_4.pdf

BAA No.: NIAID-DAIT-NIHAI201700100 Page 1 of 2 Amendment #4

Amendment No. 4

Broad Agency Announcement (BAA) No.: NIAID-DAIT-NIHAI201700100 “Vaccine Adjuvant Discovery Program”

Amendment Number: Four (4)

Amendment Issue Date: July 12, 2018

Response Date: July 31, 2018 by 3:00 PM, EST

Issued By: George Ralis

Contracting Officer

OA/DEA/NIAID/NIH/DHHS

5601 Fishers Lane, Room 3C19, MSC 9821 Rockville, Maryland 20852

Point of Contact: PRIMARY ralisg@niaid.nih.gov George Ralis, Contracting Officer Phone: 240-669-5146

Please note that we do NOT intend to extend the due date for submission of proposals as a result of this amendment. The date specified for receipt of proposals is still July 31, 2018 by 3:00 PM, EST.

Offerors must acknowledge receipt of this amendment by identifying this amendment number and date of the amendment on each copy of the proposal submitted. Failure to receive your acknowledgement may result in the rejection of your proposal. Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.

PURPOSE: This amendment is to provide responses to questions which may be useful to all potential offerors.

QUESTION/ISSUE 1:

How is the intellectual property associated with newly discovered compounds being handled?

RESPONSE:

Generally Contractors retain ownership (i.e., title) of the IP rights governing the technologies and information they develop or deliver under the Government contract while the Government receives a non-exclusive license to use the IP.

BAA No.: NIAID-DAIT-NIHAI201700100 Page 2 of 2 Amendment #4

QUESTION/ISSUE 2:

We are developing nucleic-acid based nanostructures and have found that some of them have strong adjuvant activity. We are proposing to screen nucleic acid constructs to determine sequence, shape, and configuration responsible for better adjuvant activity.

RESPONSE:

The solicitation requires the offeror to screen compound libraries in Study Area 1 but does not define the nature of the compounds to be screened for adjuvant activity. Therefore, screening nucleic acid structures as adjuvants is acceptable. Furthermore, such nucleic acid libraries can be generated by the offeror as an activity in Study Area 1.

END OF AMENDMENT NO. 4, NIAID-DAIT-NIHAI201700100